By Lina carolina 
A revolutionary new technique, Immune Lymphocyte Estimation from Nucleotide Sequencing (ImmuneLENS), developed by researchers at University College London (UCL) and the Francis Crick Institute, is poised to transform our understanding of cancer and patient prognosis. This pioneering tool allows scientists to accurately quantify T cells and B cells – crucial components of the immune system – directly from whole genome sequencing (WGS) data, a feat previously unattainable. Early findings from an analysis of over 90,000 genome samples have unveiled a striking correlation: cancer patients with a higher proportion of immune cells circulating in their blood exhibit significantly better survival rates. This discovery offers a powerful new avenue for personalized cancer diagnosis and treatment planning, potentially enhancing patient outcomes without additional costs.
The Power of ImmuneLENS: Unlocking Genetic Insights
The ImmuneLENS technology, detailed in the prestigious journal Nature Genetics, represents a significant leap forward in leveraging the vast amount of information contained within an individual’s complete DNA sequence. Whole genome sequencing, a process that meticulously maps out a person’s entire genetic blueprint from a single blood sample, has long been a cornerstone of understanding genetic predispositions and disease mechanisms. However, extracting detailed immunological data directly from this comprehensive genetic record remained an elusive challenge until the development of ImmuneLENS.
"Most immune system analysis until now has focused on the tumour itself," explained Professor Nicholas McGranahan, senior author of the study from the UCL Cancer Institute. "The results we’re seeing using this new technique – which examines the number of immune cells in a person’s blood – are of considerable interest. What’s going on with immune cells in the blood seems to have a huge impact on cancer survival and may be able to predict how long a cancer patient will survive better than the number of T cells in the tumour alone."
The methodology of ImmuneLENS involves sophisticated algorithms that can infer the presence and proportion of immune cells by analyzing patterns within the WGS data. This is achieved by identifying specific genetic signatures and variations characteristic of different immune cell types, particularly T cells and B cells, which are the primary warriors against pathogens and abnormal cells.
A Large-Scale Validation: The 100,000 Genomes Project
To rigorously test the capabilities of ImmuneLENS, the research team applied it to an unprecedented dataset: over 90,000 whole genome sequencing samples drawn from the landmark 100,000 Genomes Project. This ambitious initiative, a collaboration between Genomics England and NHS England, has systematically collected and analyzed the genomes of individuals with rare diseases and cancer, creating a rich resource for genetic research. The inclusion of data from both healthy individuals and cancer patients in this project provided the ideal backdrop for comparing immune profiles and their clinical relevance.
The analysis revealed a compelling disparity: cancer patients, on average, displayed a lower proportion of circulating T cells in their blood when compared to their healthy counterparts. This initial finding set the stage for a deeper investigation into the prognostic significance of these immune cell counts.
T Cell Proportion: A Strong Predictor of Cancer Outcomes
The study’s most impactful finding emerged from the direct correlation between T cell proportion in the blood and cancer patient survival. The researchers discovered that a higher proportion of T cells was a robust predictor of improved outcomes. Specifically, individuals with a greater abundance of T cells in their bloodstream experienced a remarkable 47% reduction in deaths over a five-year period following surgery. This significant association remained evident even when statistical models accounted for crucial confounding factors such as patient age, cancer stage, and across all cancer types examined.
"There have been hints in previous research that this might be important, but being able to analyse immune system information at this scale is game changing," Professor McGranahan emphasized. "The ability to compare immune cell changes in the blood and to what’s happening in the tumour environment opens up new avenues for cancer research, as well as healthcare research more widely."
Implications for Clinical Practice: Enhancing Diagnostic and Treatment Strategies
The potential clinical implications of ImmuneLENS are far-reaching. The researchers propose that the biological markers identified through this technique could be seamlessly integrated into existing genetic diagnostic tests without incurring additional costs. This integration would equip clinicians with a more comprehensive understanding of a patient’s immune status, thereby informing more precise and personalized treatment plans.
"In terms of patient diagnosis and treatment, knowing whether a patient has relatively high or low numbers of immune cells in the blood, and how this corresponds to their prognosis, could help clinicians to decide on the best course of treatment for the individual," Professor McGranahan elaborated.
Cancer, at its core, is a disease driven by genetic mutations that lead to uncontrolled cell growth. While the immune system is designed to detect and eliminate these aberrant cells, cancer often develops sophisticated mechanisms to evade immune surveillance and even actively suppress the immune response. Therefore, understanding both the local immune environment within the tumor and the broader systemic immune status is paramount for deciphering cancer’s progression and predicting treatment efficacy.
A Deeper Dive into Immune Cell Dynamics
The study also shed light on age-related immune changes in the context of cancer. While it is a known phenomenon that the proportion of immune cells in the blood naturally declines with age in healthy individuals, the researchers observed that this decline appears to occur earlier and more pronouncedly in people diagnosed with cancer. This accelerated immune aging could be a contributing factor to cancer development or a consequence of the disease’s impact on the body.
Interestingly, the study noted a more pronounced effect of this age-related immune cell reduction in male cancer patients compared to female patients. The precise biological reasons for these observed sexual differences remain unclear and warrant further investigation to determine if they influence overall cancer survival.
Furthermore, the analysis revealed a potential early warning sign for cancer. Individuals who appeared healthy at the time of their genome sequencing but subsequently developed cancer exhibited lower-than-average levels of B cells in their blood. This observation suggests that these individuals might have had undiagnosed early-stage cancer or pre-cancerous immune system alterations that could have served as precursors to the disease. Such insights hold significant promise for future cancer early detection strategies and for clinicians to better anticipate a patient’s response to therapy.
ImmuneLENS: A More Efficient Approach to Immune Cell Detection
Dr. Robert Bentham, the study’s first author from the UCL Cancer Institute, likened the advantage of ImmuneLENS to a more efficient method of discovery. "Lots of approaches that measure immune cells from genetic data are like looking for a needle in a haystack," he explained. "Our approach in this study instead looks at the haystack itself and asks how the presence of immune cells changes its overall shape. It’s a different, more efficient way of finding the needle."
This novel perspective allows researchers to harness existing large-scale whole genome sequencing cohorts, which were previously underutilized for immune profiling. "One of the things this will allow us to do is to build significant immune datasets using data we already have from the many large-scale WGS cohorts but haven’t been able to interrogate until now," Dr. Bentham stated. "It will allow researchers to explore what’s happening in the immune system during health and disease, not just in cancer but potentially in many areas of medicine."
Distinguishing B Cell Subtypes for Prognostic Insights
Beyond quantifying T cells, ImmuneLENS also offers the capability to distinguish between different types of B cells. B cells play a critical role in the adaptive immune response by producing antibodies, proteins that neutralize harmful substances like pathogens and mutated cells. As B cells mature, they specialize to produce specific antibody classes, a process that ImmuneLENS can effectively track within the genetic data.
When applied to WGS data, this advanced analysis revealed that B cells producing IgM/D antibodies – the type generated upon the body’s initial encounter with a foreign antigen – were uniquely associated with improved survival outcomes for cancer patients. This finding suggests a potentially significant role for these specific B cells in combating tumors. Their presence could serve as a novel biological marker for cancer diagnosis, making them a promising target for future therapeutic development.
The Path Forward: Translating Research into Clinical Impact
The research team is actively pursuing the translation of these findings into tangible clinical benefits. Professor McGranahan and his team have secured a Cancer Research UK (CRUK) funded Biomarker Project Award, which will facilitate further work to implement these discoveries in the clinic. The aspiration is to incorporate these immune cell measurements into the standard battery of tests for cancer patients at no additional financial burden.
This development is particularly significant for predicting a patient’s response to immunotherapy, a revolutionary cancer treatment that harnesses the patient’s own immune system to fight the disease. While the proportion of T cells within a tumor is a known biomarker for immunotherapy response, it cannot be currently measured using standard genomic tests. ImmuneLENS could bridge this gap, providing crucial information for optimizing immunotherapy selection and management.
Dr. Nisharnthi Duggan, Research Information Manager at Cancer Research UK, expressed optimism about the research’s potential. "Cancer Research UK is pleased to support this ongoing work investigating whether measuring immune cell levels in our blood can help predict cancer survival," she commented. "We’re living in a golden age of research where we can use patient data in sophisticated ways to help us better understand cancer and how to beat it. Further research is needed, but this could one day become a tool to help doctors personalize treatment for people with cancer."
The research is a component of the broader TRACERx project, which is also supported by Cancer Research UK. The groundbreaking insights provided by ImmuneLENS were made possible through access to the extensive data generated by the 100,000 Genomes Project, underscoring the importance of large-scale genomic initiatives in driving medical innovation. As the scientific community delves deeper into the intricate interplay between the immune system and cancer, ImmuneLENS stands as a testament to the power of technological advancement in unlocking new frontiers of understanding and ultimately improving patient care.
